Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
62 hedge funds and large institutions have $1.37B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 11 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
7% more funds holding
Funds holding: 58 → 62 (+4)
15% less capital invested
Capital invested by funds: $1.61B → $1.37B (-$234M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$14.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13.6M |
| 3 |
Bank of New York Mellon
New York
|
+$11.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$5.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$11.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$8.78M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.63M |
| 4 |
DM
Deerfield Management
New York
|
-$6.38M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.81M |
CERE Hedge Fund Activity: Q1 2021 in Review
62 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q1 2021, worth a combined $1.37B — down 15% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CERE positions and 11 closed out — a net gain of 4 holders — while 23 added to existing stakes and 14 trimmed.
The largest buyer was Federated Hermes, adding an estimated $14.6M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $11.4M sold.
- 62 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q1 2021, up from 58 in Q4 2020.
- Funds reported $1.37B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q1 2021, down 15% quarter-over-quarter.
- 15 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q1 2021 and 11 closed out, a net change of +4 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q1 2021 was Federated Hermes, an estimated $14.6M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q1 2021 was Nantahala Capital Management, an estimated $11.4M sold.
Based on aggregated 13F filings for Q1 2021.